BeOne’s Cancer Has No Borders Podcast

BeOne’s Cancer Has No Borders Podcast

Episode 11 of BeOne’s Cancer Has No Borders podcast features Pat Garcia-Gonzalez, the CEO of The Max Foundation. Watch Now

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation Announces Multi-Stakeholder Collaboration to Improve Outcomes for People Living with Advanced Breast Cancer in Low-Resource Countries

    Humanitarian Partnership for Access to Cancer Treatment (PACT) to launch in 5 countries in 2023 providing access to treatment and support for HR+/HER2- advanced breast cancer The Max Foundation, the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid and Novartis AG are joining and committing resources to a unique collaboration Breast cancer is….

  • Innovator Jerry Radich of Fred Hutch joins The Max Foundation’s Executive Board

    Innovator Jerry Radich of Fred Hutch joins The Max Foundation’s Executive Board

    The Max Foundation is thrilled to welcome longtime advisor, Dr. Jerald Radich of the Fred Hutchinson Cancer Research Institute into the Executive Board.  Dr. Radich has been a guiding star in our innovative work for many years helping people face cancer with dignity and hope, especially in the area of improving access to critical diagnostics in low- and middle-income countries.

  • The Max Foundation Renews and Expands Agreement with Incyte

    The Max Foundation Renews and Expands Agreement with Incyte

    The Max Foundation has renewed and expanded its treatment-access agreement with Incyte in Europe. The agreement will now provide treatment access for up to 50 patients in Eastern Europe and Central Asia.